Measles Virus as an Oncolytic Immunotherapy

Cancers

Guy Ungerechts¹  ChristineE. Engeland¹ 

[1] Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT) and Department of Medical Oncology, University Hospital Heidelberg, 69120 Heidelberg, Germany;

关键词: oncolytic virus;    measles virus;    cancer immunotherapy;    vector engineering;    vaccination;    immune checkpoint blockade;   

DOI  :  10.3390/cancers13030544

来源: DOAJ

【 摘 要 】

Measles virus (MeV) preferentially replicates in malignant cells, leading to tumor lysis and priming of antitumor immunity. Live attenuated MeV vaccine strains are therefore under investigation as cancer therapeutics. The versatile MeV reverse genetics systems allows for engineering of advanced targeted, armed, and shielded oncolytic viral vectors. Therapeutic efficacy can further be enhanced by combination treatments. An emerging focus in this regard is combination immunotherapy, especially with immune checkpoint blockade. Despite challenges arising from antiviral immunity, availability of preclinical models, and GMP production, early clinical trials have demonstrated safety of oncolytic MeV and yielded promising efficacy data. Future clinical trials with engineered viruses, rational combination regimens, and comprehensive translational research programs will realize the potential of oncolytic immunotherapy.

【 授权许可】

Unknown